- Citations, last 5 years
- 116
- Works, last 5 years
- 5
- h-index
- 38
- Scientists listed
- 1
- Grants since 2016
- 12
Grants received
2020–2021 · research · R44
Cindi Study: A Phase II Clinical Trial to Combine CD24Fc with Ipilimumab and Nivolumab to Decrease Immune Related Adverse Events (irAE)
Siwen Hu-Lieskovan · OncoImmune (United States) · funded by National Institutes of Health
2020 · research · R44
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
Christian Diego Rolfo · OncoImmune (United States) · funded by National Institutes of Health
2019–2021 · research · R44
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
2019–2021 · research · R44
A phase II dose expansion clinical trial testing the efficacy of CD24Fc for the prophylaxis of severe graft vs host disease and leukemia relapse
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
2019–2021 · research · R44
A randomized, placebo-controlled, single-blinded clinical trial to assess safety and efficacy of CD24Fc in controlling cardiovascular disease risks of HIV-infected patients
Shyamasundaran Kottilil · OncoImmune (United States) · funded by National Institutes of Health
2019–2021 · research · R44
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
2019–2020 · research · R41
Evaluation of therapeutic efficacy and safety of novel small RNA target delivery platform in vivo.
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
2018–2021 · research · R01
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)
Yang Liu · OncoImmune (United States) · funded by U.S. Food and Drug Administration
2018–2022 · research · R01
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/2016)
Yang Liu · OncoImmune (United States) · funded by U.S. Food and Drug Administration
2017–2019 · research · R44
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
2017–2019 · research · R44
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
2017–2020 · research · R44
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
Martin Devenport · OncoImmune (United States) · funded by National Institutes of Health
